Actively Recruiting
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Led by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Updated on 2025-02-24
300
Participants Needed
1
Research Sites
1025 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
CONDITIONS
Official Title
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) for Mantle Cell Lymphoma (MCL) according to FDA-approved dose and specifications for commercial release in the USA
You will not qualify if you...
- Participants known to be participating in investigational studies at the time of liso-cel infusion
- Participants treated with non-conforming CAR T-cell product
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for International Blood and Marrow Transplant Research (CIBMTR)
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here